Professor | Bo Yang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Bo Yang
Contact Information	yang924@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Bo Yang

Contact Information

yang924@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	National Outstanding Youth Fund recipient Recipient of the State Council Special Government Allowance Selected for the National Ten Thousand Talents Program Published 117 papers in journals such as JCI, Blood, Hepatology, Cell Research, STTT, Cancer Research Cited over 7000 times Undertaken 16 national projects Developed 17 innovative drugs Received 4 clinical trial approvals for new drugs Authorized 69 invention patents (including 7 international patents) Received 16 scientific and technological awards including the Zhejiang Provincial Natural Science First Prize
Awards	2022 Zhejiang Provincial Natural Science First Prize: Research on new mechanisms and targets for tumor regulation based on protein homeostasis 2018 Ministry of Education Higher Education Scientific Research Outstanding Achievement Award Second Prize: Discovery of anti-tumor drug targets targeting the hypoxic microenvironment of tumors 2016 Zhejiang Provincial Natural Science Third Prize: Research on the combination of anti-tumor drugs based on molecular targets 2014 Zhejiang Provincial Natural Science Second Prize: Research on the anti-tumor effects of retinoic acid and its derivatives 2014 Ministry of Education Science and Technology Progress Second Prize: Research on key technologies and models for ADMET druggability evaluation 2014 Chinese Pharmaceutical Association Science and Technology Second Prize: Research on key technologies and models for ADMET druggability evaluation 2014 Chinese Pharmaceutical Association Science and Technology Third Prize: Evaluation and mechanism research of anti-tumor drug activity based on molecular targets 2011 Zhejiang Provincial Natural Science Second Prize: Discovery and development of new anti-tumor drugs targeting topoisomerase 2011 Zhejiang Provincial Natural Science Third Prize: Design and development of innovative drugs for anti-senile dementia based on targets 2010 Zhejiang Provincial Natural Science Second Prize: Design and discovery of targeted anti-tumor drugs 2008 Zhejiang Provincial Natural Science Second Prize: Establishment and application of anti-tumor drug activity evaluation methods based on targets

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

National Outstanding Youth Fund recipient
Recipient of the State Council Special Government Allowance
Selected for the National Ten Thousand Talents Program
Published 117 papers in journals such as JCI, Blood, Hepatology, Cell Research, STTT, Cancer Research
Cited over 7000 times
Undertaken 16 national projects
Developed 17 innovative drugs
Received 4 clinical trial approvals for new drugs
Authorized 69 invention patents (including 7 international patents)
Received 16 scientific and technological awards including the Zhejiang Provincial Natural Science First Prize

Awards

2022 Zhejiang Provincial Natural Science First Prize: Research on new mechanisms and targets for tumor regulation based on protein homeostasis
2018 Ministry of Education Higher Education Scientific Research Outstanding Achievement Award Second Prize: Discovery of anti-tumor drug targets targeting the hypoxic microenvironment of tumors
2016 Zhejiang Provincial Natural Science Third Prize: Research on the combination of anti-tumor drugs based on molecular targets
2014 Zhejiang Provincial Natural Science Second Prize: Research on the anti-tumor effects of retinoic acid and its derivatives
2014 Ministry of Education Science and Technology Progress Second Prize: Research on key technologies and models for ADMET druggability evaluation
2014 Chinese Pharmaceutical Association Science and Technology Second Prize: Research on key technologies and models for ADMET druggability evaluation
2014 Chinese Pharmaceutical Association Science and Technology Third Prize: Evaluation and mechanism research of anti-tumor drug activity based on molecular targets
2011 Zhejiang Provincial Natural Science Second Prize: Discovery and development of new anti-tumor drugs targeting topoisomerase
2011 Zhejiang Provincial Natural Science Third Prize: Design and development of innovative drugs for anti-senile dementia based on targets
2010 Zhejiang Provincial Natural Science Second Prize: Design and discovery of targeted anti-tumor drugs
2008 Zhejiang Provincial Natural Science Second Prize: Establishment and application of anti-tumor drug activity evaluation methods based on targets

Areas of Focus	Tumor Pharmacology Innovative Drug Research
Publications	Canagliflozin primes anti-tumor immunity by triggering PD-L1 degradation in endocytic recycling, Ling Ding, Xi Chen, Wenxin Zhang, Xiaoyang Dai, Hongjie Guo, Xiaohui Pan, Yanjun Xu, Jianguo Feng, Meng Yuan, Xiaomeng Gao, Jian Wang, Sicheng Li, Honghai Wu, Ji Cao, Qiaojun He, Bo Yang, 2023 SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ, Yuan T, Zhou T, Qian M, Du J, Liu Y, Wang J, Li Y, Fan G, Yan F, Dai X, Li X, Wu Y, Dong X, He Q, Zhu H, Yang B, 2023 Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity, Yuan T, Zeng C, Liu J, Zhao C, Ge F, Li Y, Qian M, Du J, Wang W, Li Y, Liu Y, Dai X, Zhou J, Chen X, Ma S, Zhu H, He Q, Yang B, 2023 s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide, Luo P, Yan H, Chen X, Zhang Y, Zhao Z, Cao J, Zhu Y, Du J, Xu Z, Zhang X, Zeng S, Yang B, Ma S, He Q, 2020 Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2, Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, Chen Y, Xiang S, Song H, Hu R, Wei G, Yang B, He Q, 2018 PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1), Luo P, Yan H, Du J, Chen X, Shao J, Zhang Y, Xu Z, Jin Y, Lin N, Yang B, He Q, 2021 HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport, Luo P, Xu Z, Li G, Yan H, Zhu Y, Zhu H, Ma S, Yang B, He Q, 2018 Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma, Liu X, Cai T, Zhu H, Cao J, Su Y, Hu Y, He Q, Yang B, 2014 USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ, Zhu H, Yan F, Yuan T, Qian M, Zhou T, Dai X, Cao J, Ying M, Dong X, He Q, Yang B, 2020 Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis, Zhu H, Wang DD, Yuan T, Yan FJ, Zeng CM, Dai XY, Chen ZB, Chen Y, Zhou T, Fan GH, Ying M, Cao J, Luo P, Liu XJ, Hu Y, Peng Y, He Q, Yang B, 2018

Areas of Focus

Tumor Pharmacology
Innovative Drug Research

Publications

Canagliflozin primes anti-tumor immunity by triggering PD-L1 degradation in endocytic recycling, Ling Ding, Xi Chen, Wenxin Zhang, Xiaoyang Dai, Hongjie Guo, Xiaohui Pan, Yanjun Xu, Jianguo Feng, Meng Yuan, Xiaomeng Gao, Jian Wang, Sicheng Li, Honghai Wu, Ji Cao, Qiaojun He, Bo Yang, 2023
SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ, Yuan T, Zhou T, Qian M, Du J, Liu Y, Wang J, Li Y, Fan G, Yan F, Dai X, Li X, Wu Y, Dong X, He Q, Zhu H, Yang B, 2023
Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity, Yuan T, Zeng C, Liu J, Zhao C, Ge F, Li Y, Qian M, Du J, Wang W, Li Y, Liu Y, Dai X, Zhou J, Chen X, Ma S, Zhu H, He Q, Yang B, 2023
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide, Luo P, Yan H, Chen X, Zhang Y, Zhao Z, Cao J, Zhu Y, Du J, Xu Z, Zhang X, Zeng S, Yang B, Ma S, He Q, 2020
Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2, Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, Chen Y, Xiang S, Song H, Hu R, Wei G, Yang B, He Q, 2018
PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1), Luo P, Yan H, Du J, Chen X, Shao J, Zhang Y, Xu Z, Jin Y, Lin N, Yang B, He Q, 2021
HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport, Luo P, Xu Z, Li G, Yan H, Zhu Y, Zhu H, Ma S, Yang B, He Q, 2018
Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma, Liu X, Cai T, Zhu H, Cao J, Su Y, Hu Y, He Q, Yang B, 2014
USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ, Zhu H, Yan F, Yuan T, Qian M, Zhou T, Dai X, Cao J, Ying M, Dong X, He Q, Yang B, 2020
Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis, Zhu H, Wang DD, Yuan T, Yan FJ, Zeng CM, Dai XY, Chen ZB, Chen Y, Zhou T, Fan GH, Ying M, Cao J, Luo P, Liu XJ, Hu Y, Peng Y, He Q, Yang B, 2018

Tumor Pharmacology Drug Mechanism Innovative Drugs Target Discovery Protein Homeostasis Toxicity Intervention Cancer Research Drug Development Clinical Trials

Hong Zhu - Zhejiang University

Yi-Zhun Zhu - Fudan University

Yuan Gao - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us